Yan Zhu

Yan Zhu

Auto-generated profile, based on publicly available information

Yan Zhu

Molecular Cancer Research Center, School of Medicine, Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Open Biology
Verified
Journal Article
Open access
YZYan Zhu
Yan Zhu
LALUKMAN AFOLABI
LUKMAN AFOLABI
XWXiaochun Wan
Xiaochun Wan
JSJoong Sup Shim
Joong Sup Shim
LCLiang Chen
Liang Chen
Neurodegenerative diseases (NDs) are a diverse group of disorders characterized by the progressive degeneration of the structure and function of the central or peripheral nervous systems. One of the major features of NDs, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), is the aggregation of specific misfolded proteins, which induces cellular dysfunction, neuronal death, loss of synaptic connections and eventually brain damage. By far, a great amount of evidence has suggested that TRIM family proteins play crucial roles in the turnover of normal regulatory and misfolded proteins. To maintain cellular protein quality control, cells rely on two major classes of proteostasis: molecular chaperones and the degradative systems, the latter includes the ubiquitin-proteasome system (UPS) and autophagy; and their dysfunction has been established to result in various physiological disorders including NDs. Emerging evidence has shown that TRIM proteins are key players in facilitating the clearance of misfolded protein aggregates associated with neurodegenerative disorders. Understanding the different pathways these TRIM proteins employ during episodes of neurodegenerative disorder represents a promising therapeutic target. In this review, we elucidated and summarized the diverse roles with underlying mechanisms of members of the TRIM family proteins in NDs.

1 May 2018 in Journal of Alloys and Compounds
Verified
Journal Article
Closed access
HSHaojie Song
Haojie Song
TWTian Wang
Tian Wang
XJXiaohua Jia
Xiaohua Jia
YZYan Zhu
Yan Zhu

24 March 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
YZYan Zhu
Yan Zhu
MLMaoxuan Liu
Maoxuan Liu
XFXiaokai Fan
Xiaokai Fan
YXYingying Xu
Yingying Xu
XDXueling Diao
Xueling Diao
LCLiang Chen
Liang Chen
Background: Immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) immunotherapies have revolutionized the treatment of hepatocellular carcinoma (HCC). However, the frequent emergence of treatment resistance significantly limits the clinical efficacy of HCC immunotherapy. The molecular mechanisms underlying therapy resistance remain poorly understood. Methods: To delineate the immune impact of nuclear factor erythroid 2-related factor 2 (Nrf2) inhibition, we integrated allograft tumor models with bulk and single-cell RNA sequencing analyses. Biochemical assays were performed to investigate the mechanisms underlying Nrf2 inhibition in immune resistance. The combined activity of Nrf2 inhibition with anti-programmed death-1 (PD-1) antibody and CAR-T cell therapy was also explored in vivo. Results: We show that brusatol (BRU), a specific inhibitor of Nrf2, an emerging regulator of the tumor immune microenvironment, potentiates antitumor immunity in HCC mouse models. Mechanistically, inhibition of Nrf2 downregulates surface programmed death ligand-1 (PD-L1) expression via transcriptional repression in tumor cells, while upregulating major histocompatibility complex (MHC)-I expression via nuclear factor kappa-light-chain-enhancer of activated B cells activation. Inhibition of Nrf2 in tumor cells enhances the activation of immune-related signaling pathways and promotes CD8 + T-cell infiltration into tumor tissues. Furthermore, inhibition of Nrf2 with BRU significantly enhances the efficacy of PD-1 antibody and CAR-T cells against HCC in vivo, indicating that therapeutic targeting of Nrf2 in HCC cells sensitizes them to ICIs and CAR-T immunotherapies. Conclusions: Our findings offer a novel strategy to enhance HCC immunotherapy by blocking Nrf2, which has the potential to address the low response rates observed with current HCC immunotherapies.

2 August 2021
Verified
Conference Paper
Closed access
GSGuobin Sun
Guobin Sun
Jin ZhangJin Zhang
Jin Zhang
YLYang Liu
Yang Liu
XJXuesong Ji
Xuesong Ji
YZYan Zhu
Yan Zhu
Sub-wavelength microstructure optical devices based on silicon grating structure have unique spectral characteristics, which can produce the enhanced absorption performance of visible wide band. According to the extremely low absorption in NIR wide band $0.78-2.5 \mu \mathrm{m}$ , this paper proposes two composite microstructures which contain silicon grating and Ag nano-sphere or nano-pit based on surface plasmon resonance to produce optical absorption enhancement. The simulation results based on Finite Difference Time Domain method show that When the Ag nano-sphere and the Ag nano-pit are added to the silicon column micro-structure, the combined microstructure is all above 9.3% in NIR band, and the highest absorption rate can achieve 95.6% theoretically. The layer Al 2 O 3 is increased in the grating surface according to the equivalent medium theory, and that result in the absorption efficiency of both composite microstructures is improved in NIR band. In conclusion, this paper provides a new method to enhance optical absorption in photodetectors, solar cells, optical communication, biomedicine and other fields.

20 May 2026 in Molecular Therapy Oncology
Verified
Journal Article
Open access
YZYan Zhu
Yan Zhu
MLMaoxuan Liu
Maoxuan Liu
Hang Fai (Henry) KwokHang Fai (Henry) Kwok
Hang Fai (Henry) Kwok
LCLiang Chen
Liang Chen